Trials with medicinal products
ALLTogether1 (ALL) Clinical study concerning the ALLTogether1 treatment protocol for children and young adults with acute lymphoblastic leukemia (ALL) - open for inclusion
AMoRe2017 (AML) Clinical study of the safety and efficacy of azacitidine in children and adolescents with a molecular relapse of acute myeloid leukemia (AML) - open for inclusion
Blinatumomab (infant ALL) Clinical study of the feasibility, safety and efficacy of adding blinatumomab to the standard treatment of infants with MLL-rearranged acute lymphoblastic leukemia (ALL) - closed for inclusion
Bosutinib (CML) Clinical study of the safety and efficacy of bosutinib in children and teenagers with chronic myeloid leukemia (CML) - open for inclusion
CABL001i12201 (CML) Clinical study to determine the dose and safety of asciminib in children and adolescents with chronic myeloid leukemia in the chronic phase - open for inclusion
Carfilzomib (relapsed/refractory ALL) Clinical study of carfilzomib in children with relapsed or refractory leukemia - open for inclusion
CASSIOPEIA (B-ALL) Clinical study with the new tisagenlecleucel treatment in children and adolescents with B-cell acute lymphoblastic leukemia - open for inclusion
CHIP-AML22/Master (Acute Myeloid Leukemia) Clinical study concerning the treatment of children and adolescents with newly diagnosed acute myeloid leukemia (AML) - open for inclusion
ESMART (different tumor types) Clinical study in children with cancer into the safety and efficacy of drugs matching a specific DNA alteration in the tumor - open for inclusion
ICC APL 02 (Acute Promyelocytic Leukemia) Clinical study of the treatment of Acute Promyelocytic Leukemia (APL) - open for inclusion
Idasanutlin (acute leukemia/solid tumors) Clinical study of idasanutlin in combination with chemotherapy or venetoclax in children who have unresponsive or recurrent acute leukemia or solid tumors - open for inclusion
Inotuzumab B1931036 (ALL) Clinical study of inotuzumab ozogamicin in children with a diagnosis of first relapse high-risk acute lymphoblastic leukemia - open for inclusion
Inotuzumab ITCC-059 (ALL/B-cell leukemia/lymphoma) Clinical study of the safety and efficacy of the drug Inotuzumab Ozogamicin (InO) in children with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) or other CD22-positive malignancies - open for inclusion
Interfant-21 (ALL) Clinical study for infants with acute lymphoblastic leukemia with a KMT2A gene rearrangment - open for inclusion
JCAR017-BCM-004 (B-ALL/B-NHL) Clinical study to evaluate the safety and efficacy of JCAR017 in children with a special type of leukemia (B-ALL) and non-Hodgkin’s lymphoma - open for inclusion
Ponatinib-1501 (Ph+ ALL) Clinical study of the safety and efficacy of ponatinib with chemotherapy in children with Ph+ acute lymphoblastic leukemia (ALL) - open for inclusion
Ponatinib INCB084344 (leukemia/solid tumors) Clinical study of the safety and efficacy of ponatinib for the treatment of different types of leukemia or solid tumors in children - open for inclusion
Quizartinib (AML) Clinical study of the safety and efficacy of quizartinib in combination with chemotherapy in children and young adults with AML and FLT3-ITD mutations - open for inclusion
SNDX-5613-0700 (relapsed/refractory leukemias) Clinical study of SNDX-5613 in patients with leukemias - open for inclusion
TCD17197 (R/R AML) Clinical study of safety and efficacy of the study drug SAR443579 in patients with leukemia - open for inclusion
Venetoclax ITCC-101/APAL2020D (AML) Clinical study of the efficacy of the drug venetoclax in children and young adults with relapsed AML - open for inclusion
Venetoclax M13-833 (hematologic/solid tumors) Clinical study of the safety and efficacy of the drug venetoclax in children and young adults - closed for inclusion
VyClo (ITCC-092) (AML) Clinical study of the safety of the drug Vyxeos® (liposomal daunorubicin and cytarabine) in combination with clofarabine in children and young adults with relapsed/refractory acute myeloid leukemia (AML) - open for inclusion
ZUMA-4 (ALL/NHL) Clinical study of the safety and efficacy of KTE-X19 in pediatric and adolescent subjects with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) - open for inclusion
Other trials
Breath analysis (hemato-oncological disease) A clinical pilot study of exhaled breath as an approach in the diagnostic work-up for an invasive fungal infection in the lungs of children with an impaired immune system - open for inclusion
FOCUS Clinical study to optimize dosing of fluconazole in children for the prevention or treatment of invasive fungal infections - open for inclusion
FOLLOW-ON study (ALL) Clinical study investigating the long-term outcome of childhood acute lymphoblastic leukemia (ALL) survivors who have experienced symptomatic osteonecrosis during or shortly after discontinuation of treatment - open for inclusion
International Leukemia/Lymphoma Target Board (iLTB) for relapsed and refractory leukemia/lymphoma An international platform of experts that aims to make access to drug trials for children with relapsed or refractory leukemia and lymphoma as standardized as possible - open for inclusion
PINOCCHIO (multiple types of cancer) Clinical study in children on the metabolism, distribution and excretion of chemotherapy in the body, also called pharmacokinetics - open for inclusion
Tumor donation in Childhood Cancer patients This study is designed to enable post-mortem tumor donation in children who die from all different types of pediatric solid and brain tumors, to enable research on end-stage disease - open for inclusion
VIKinG (AML & Burkitt lymphoma) Clinical study of the gut microbiota as predictor for bloodstream infections in children with cancer - open for inclusion